The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Epoprostenol
Epoprostenol · EPOPROSTENOL 1.5 mg/10mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Mylan Institutional LLC
NDC 67457-0588-10 · 1 VIAL in 1 CARTON / 10 mL in 1 VIAL · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$44.50
Reported to Texas DSHS · 2026 annual filing · Mylan Institutional Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 0.5 MG
$16.918
HCPCS J1325 · Jul 1, 2026 quarter · typically ASP + 6%
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA213913
- TE code
- AP2
- Approval date
- Jun 12, 2024
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Epoprostenol (Injection, Powder, Lyophilized, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | EPOPROSTENOL .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Actelion Pharmaceuticals US, Inc. | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Gland Pharma Limited | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Gland Pharma Limited | EPOPROSTENOL .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional LLC | EPOPROSTENOL .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional LLC | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | EPOPROSTENOL SODIUM .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | EPOPROSTENOL SODIUM 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Wasserburger Arzneimittelwerk GmbH | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Epoprostenol — NDC 67457-0588-10," retrieved September 3, 2026, https://drugdashboards.com/drug/67457058810.
Free to cite with attribution — see how the data is put together.